Antiarrhythmic properties of ranolazine: A review of the current evidence

International Journal of Cardiology

Volumn 187, Issue 1, 2015, Pages 66-74

  Gupta, Tanush ^a   Khera, Sahil ^a   Kolte, Dhaval ^a   Aronow, Wilbert S ^a   Iwai, Sei ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Atrial fibrillation; Late sodium current; Peak sodium current; Ranolazine; Ventricular tachycardia

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; DELAYED RECTIFIER POTASSIUM CHANNEL; DRONEDARONE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ION CHANNEL; LIDOCAINE; PLACEBO; RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SOTALOL; SODIUM CHANNEL BLOCKING AGENT;

ANTIARRHYTHMIC ACTIVITY; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG POTENTIATION; HEART ATRIUM ARRHYTHMIA; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IC50; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM CURRENT; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; ATRIAL FIBRILLATION; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY;

ATRIAL FIBRILLATION; HEART CONDUCTION SYSTEM; HUMANS; RANOLAZINE; SODIUM CHANNEL BLOCKERS;

EID: 84929157745     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.324     Document Type: Review

References (87)

1. S. Khera, D. Kolte, W.S. Aronow, Use of ranolazine in patients with stable angina pectoris, Cardiology 128 (2014) 251-258.
2. D.T. Nash, S.D. Nash, Ranolazine for chronic stable angina, Lancet 372 (2008) 1335-1341.
3. B.R. Chaitman, Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions, Circulation 113 (2006) 2462-2472.
4. G. Savarese, G. Rosano, C. D'Amore, et al., Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis, Int. J. Cardiol. 169 (2013) 262-270.
5. M. Cattaneo, A.P. Porretta, A. Gallino, Ranolazine: Drug overview and possible role in primary microvascular angina management, Int. J. Cardiol. 181C (2014) 376-381.
6. R.M. Gowda, I.A. Khan, G. Punukollu, B.C. Vasavada, C.K. Nair, Treatment of refractory angina pectoris, Int. J. Cardiol. 101 (2005) 1-7.
7. C. Zuchi, I. Tritto, G. Ambrosio, Angina pectoris in women: Focus on microvascular disease, Int. J. Cardiol. 163 (2013) 132-140.
8. G. Marazzi, M. Volterrani, G.M. Rosano, Metabolic agents in the management of diabetic coronary patients: A new era, Int. J. Cardiol. 127 (2008) 124-125.
9. E. Vizzardi, A. D'Aloia, F. Quinzani, et al., A focus on antiarrhythmic properties of ranolazine, J. Cardiovasc. Pharmacol. Ther. 17 (2012) 353-356.
10. G. Frommeyer, P. Milberg, L.S. Maier, L. Eckardt, Late sodium current inhibition: The most promising antiarrhythmic principle in the near future? Curr. Med. Chem. 21 (2014) 1271-1280.
11. J. Camm, Antiarrhythmic drugs for themaintenance of sinus rhythm: Risks and benefits, Int. J. Cardiol. 155 (2012) 362-371.
12. S.A. Shah, G. Koyama, D. Da Costa, P. McGregor, M. Kolasa, Combination use of ranolazine with dofetilide for the maintenance of atrial fibrillation, Int. J. Cardiol. 172 (2014) e428-e429.
13. M.P. van den Berg, F. van den Heuvel, J.P. van Tintelen, P.G. Volders, I.C. van Gelder, Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker, Int. J. Cardiol. 171 (2014) 90-92.
14. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt, et al., Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties, Circulation 110 (2004) 904-910.
15. Y. Song, J.C. Shryock, L. Wu, L. Belardinelli, Antagonism by ranolazine of the proarrhythmic effects of increasing late INa in guinea pig ventricular myocytes, J. Cardiovasc. Pharmacol. 44 (2004) 192-199.
16. A.I. Undrovinas, L. Belardinelli, N.A. Undrovinas, H.N. Sabbah, Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current, J. Cardiovasc. Electrophysiol. 17 (Suppl. 1) (2006) S169-S177.
17. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, C. Antzelevitch, Atriumselective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodiumchannel inactivation between atria and ventricles and the role of ranolazine, Circulation 116 (2007) 1449-1457.
18. S. Sossalla, B. Kallmeyer, S. Wagner, et al., Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium, J. Am. Coll. Cardiol. 55 (2010) 2330-2342.
19. C. Antzelevitch, A. Burashnikov, S. Sicouri, L. Belardinelli, Electrophysiologic basis for the antiarrhythmic actions of ranolazine, Heart Rhythm. 8 (2011) 1281-1290.
20. E. Coraboeuf, E. Deroubaix, A. Coulombe, Effect of tetrodotoxin on action potentials of the conducting system in the dog heart, Am. J. Physiol. 236 (1979) H561-H567.
21. A. Burashnikov, C. Antzelevitch, Role of late sodium channel current block in the management of atrial fibrillation, Cardiovasc. Drugs Ther. 27 (2013) 79-89.
22. A. Undrovinas, V.A. Maltsev, Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart, Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 348-359.
23. A.C. Zygmunt, G.T. Eddlestone, G.P. Thomas, V.V. Nesterenko, C. Antzelevitch, Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle, Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H689-H697.
24. A.I. Undrovinas, I.A. Fleidervish, J.C. Makielski, Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine, Circ. Res. 71 (1992) 1231-1241.
25. J.Wu, P.B. Corr, Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes, Am. J. Physiol. 266 (1994) H1034-H1046.
26. S. Sossalla, S. Wagner, E.C. Rasenack, et al., Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation, J. Mol. Cell. Cardiol. 45 (2008) 32-43.
27. B. Huang, T. El-Sherif, M. Gidh-Jain, D. Qin, N. El-Sherif, Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium, J. Cardiovasc. Electrophysiol. 12 (2001) 218-225.
28. V.A. Maltsev, N. Silverman, H.N. Sabbah, A.I. Undrovinas, Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability, Eur. J. Heart Fail. 9 (2007) 219-227.
29. S. Wagner, N. Dybkova, E.C. Rasenack, et al., Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels, J. Clin. Invest. 116 (2006) 3127-3138.
30. S. Wagner, H.M. Ruff, S.L. Weber, et al., Reactive oxygen species-activated Ca/calmodulin kinase IIdelta is required for late I(Na) augmentation leading to cellular Na and Ca overload, Circ. Res. 108 (2011) 555-565.
31. X.Q. Zhang, S. Yamada, W.H. Barry, Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia, J. Cardiovasc. Pharmacol. 51 (2008) 443-449.
32. K. Toischer, A.G. Rokita, B. Unsold, et al., Differential cardiac remodeling in preload versus afterload, Circulation 122 (2010) 993-1003.
33. C.A. Ward, W.R. Giles, Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes, J. Physiol. 500 (Pt 3) (1997) 631-642.
34. Y. Song, J.C. Shryock, S.Wagner, L.S. Maier, L. Belardinelli, Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction, J. Pharmacol. Exp. Ther. 318 (2006) 214-222.
35. S. Fredj, N. Lindegger, K.J. Sampson, P. Carmeliet, R.S. Kass, Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes, Circ. Res. 99 (2006) 1225-1232.
36. A.C. Zygmunt, V.V. Nesterenko, S. Rajamani, et al., Mechanisms of atrial-selective block of Na(+) channels by ranolazine: I. Experimental analysis of the usedependent block, Am. J. Physiol. Heart Circ. Physiol. 301 (2011) H1606-H1614.
37. S. Sossalla, L.S. Maier, Role of ranolazine in angina, heart failure, arrhythmias, and diabetes, Pharmacol. Ther. 133 (2012) 311-323.
38. B.R. Chaitman, S.L. Skettino, J.O. Parker, et al., Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina, J. Am. Coll. Cardiol. 43 (2004) 1375-1382.
39. B.R. Chaitman, C.J. Pepine, J.O. Parker, et al., Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial, JAMA 291 (2004) 309-316.
40. M. Kosiborod, S.V. Arnold, J.A. Spertus, et al., Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: Results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina), J. Am. Coll. Cardiol. 61 (2013) 2038-2045.
41. M.J. Koren, M.R. Crager, M. Sweeney, Long-term safety of a novel antianginal agent in patientswith severe chronic stable angina: The Ranolazine Open Label Experience (ROLE), J. Am. Coll. Cardiol. 49 (2007) 1027-1034.
42. P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, L. Meng, E. Investigators, Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial, J. Am. Coll. Cardiol. 48 (2006) 566-575.
43. S.R. Wilson, B.M. Scirica, E. Braunwald, et al., Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-STSegment Elevation Acute Coronary Syndromes) 36 trial, J. Am. Coll. Cardiol. 53 (2009) 1510-1516.
44. S. Sicouri, A. Glass, L. Belardinelli, C. Antzelevitch, Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations, Heart Rhythm. 5 (2008) 1019-1026.
45. K. Kumar, B.D. Nearing, M. Carvas, et al., Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart, J. Cardiovasc. Electrophysiol. 20 (2009) 796-802.
46. M. Carvas, B.C. Nascimento, M. Acar, B.D. Nearing, L. Belardinelli, R.L. Verrier, Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart, J. Cardiovasc. Pharmacol. 55 (2010) 286-291.
47. C. Antzelevitch, A. Burashnikov, Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation, J. Electrocardiol. 42 (2009) 543-548.
48. C.E. Woods, J. Olgin, Atrial fibrillation therapy now and in the future: Drugs, biologicals, and ablation, Circ. Res. 114 (2014) 1532-1546.
49. D.S. Echt, P.R. Liebson, L.B. Mitchell, et al.,Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial, N. Engl. J. Med. 324 (1991) 781-788.
50. W.C. Tsai, Y.C. Chen, Y.H. Kao, Y.Y. Lu, S.A. Chen, Y.J. Chen, Distinctive sodium and calciumregulation associated with sex differences in atrial electrophysiology of rabbits, Int. J. Cardiol. 168 (2013) 4658-4666.
51. A. Burashnikov, S. Sicouri, J.M. Di Diego, L. Belardinelli, C. Antzelevitch, Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation, J. Am. Coll. Cardiol. 56 (2010) 1216-1224.
52. S. Sicouri, A. Burashnikov, L. Belardinelli, C. Antzelevitch, Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria, Circ. Arrhythm. Electrophysiol. 3 (2010) 88-95.
53. D.K. Murdock, N. Overton, M. Kersten, J. Kaliebe, F. Devecchi, The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation, Indian Pacing Electrophysiol. J. 8 (2008) 175-181.
54. D.K.Murdock, M. Kersten, J. Kaliebe, G. Larrain, The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation, Indian Pacing Electrophysiol. J. 9 (2009) 260-267.
55. R.H. Miles, R. Passman, D.K. Murdock, Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting, Am. J. Cardiol. 108 (2011) 673-676.
56. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, et al., Effects of ranolazine on recurrent cardiovascular events in patientswith non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial, JAMA 297 (2007) 1775-1783.
57. B.M. Scirica, D.A. Morrow, H. Hod, et al., Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial, Circulation 116 (2007) 1647-1652.
58. B.M. Scirica, L. Belardinelli, B.R. Chaitman, et al., Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: Observations from the MERLIN-TIMI 36 trial, Europace 17 (1) (2015) 32-37.
59. The HARMONY Study 2014Available from: Http://www.gilead.com/news/press-releases/2014/5/gilead-announces-results-from-phase-2-study-showing-reductionin-atrial-fibrillation-burden-with-the-investigational-combination-of-ranolazineand-lowdose-dronedarone (20 September 2014, date last accessed).
60. A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)Available from: Http://clinicaltrials.gov/show/NCT01522651 (20 September 2014, date last accessed).
61. Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion (RAFFAELLO) Available from: Http://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002789-18/IT (20 September 2014, date last accessed).
62. Y. Song, J.C. Shryock, L. Belardinelli, An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H2031-H2039.
63. N.A. Undrovinas, V.A. Maltsev, L. Belardinelli, H.N. Sabbah, A. Undrovinas, Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure, J. Physiol. Sci. 60 (2010) 245-257.
64. J.A. Wasserstrom, R. Sharma, M.J. O'Toole, et al., Ranolazine antagonizes the effects of increased late sodium current on intracellular calcium cycling in rat isolated intact heart, J. Pharmacol. Exp. Ther. 331 (2009) 382-391.
65. L. Wu, S. Rajamani, H. Li, C.T. January, J.C. Shryock, L. Belardinelli, Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1048-H1057.
66. P. Milberg, C. Pott, M. Fink, et al., Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3, Heart Rhythm. 5 (2008) 1444-1452.
67. L. Wu, J.C. Shryock, Y. Song, Y. Li, C. Antzelevitch, L. Belardinelli, Antiarrhythmic effects of ranolazine in a guinea pig in vitromodel of long-QT syndrome, J. Pharmacol. Exp. Ther. 310 (2004) 599-605.
68. L. Wu, J.C. Shryock, Y. Song, L. Belardinelli, An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts, J. Pharmacol. Exp. Ther. 316 (2006) 718-726.
69. G. Antoons, A. Oros, J.D. Beekman, et al., Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model, J. Am. Coll. Cardiol. 55 (2010) 801-809.
70. C. Antzelevitch, L. Belardinelli, L.Wu, et al., Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent, J. Cardiovasc. Pharmacol. Ther. 9 (Suppl. 1) (2004) S65-S83.
71. K. Kumar, B.D. Nearing, C.R. Bartoli, K.F. Kwaku, L. Belardinelli, R.L. Verrier, Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart, J. Cardiovasc. Electrophysiol. 19 (2008) 1073-1079.
72. A.K. Dhalla,W.Q.Wang, J. Dow, et al., Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1923-H1929.
73. R.A. Kloner, J.S. Dow, A. Bhandari, First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model, J. Cardiovasc. Pharmacol. Ther. 16 (2011) 192-196.
74. T. Nieminen, D.Y. Nanbu, I.P. Datti, et al., Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model, Heart Rhythm. 8 (2011) 608-614.
75. N. Morita, J.H. Lee, Y. Xie, et al., Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine, J. Am. Coll. Cardiol. 57 (2011) 366-375.
76. G. Frommeyer, S. Rajamani, F. Grundmann, et al., New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: Prevention of ventricular fibrillation with increased postrepolarization refractoriness and without druginduced proarrhythmia, J. Card. Fail. 18 (2012) 939-949.
77. G. Frommeyer, D. Kaiser, T. Uphaus, et al., Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits, Heart Rhythm. 9 (2012) 2051-2058.
78. W.Q. Wang, C. Robertson, A.K. Dhalla, L. Belardinelli, Antitorsadogenic effects of ({+/?})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits, J. Pharmacol. Exp. Ther. 325 (2008) 875-881.
79. L. Wu, D. Guo, H. Li, et al., Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine, Heart Rhythm. 5 (2008) 1726-1734.
80. S. Jia, J. Lian, D. Guo, et al., Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade, Br. J. Pharmacol. 164 (2011) 308-316.
81. A.J. Moss, W. Zareba, K.Q. Schwarz, S. Rosero, S. McNitt, J.L. Robinson, Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome, J. Cardiovasc. Electrophysiol. 19 (2008) 1289-1293.
82. T.J. Bunch, S.Mahapatra, D. Murdock, et al., Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks, Pacing Clin. Electrophysiol. 34 (2011) 1600-1606.
83. B.M. Scirica, E. Braunwald, L. Belardinelli, et al., Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: Observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial, Circulation 122 (2010) 455-462.
84. Ranolazine Implantable Cardioverter-Defibrillator Trial (RAID)Available from: Http://clinicaltrials.gov/show/NCT01215253 (20 September 2014, date last accessed).
85. G. Frommeyer, M. Schmidt, C. Clauss, et al., Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimentalmodel of chronic heart failure, Eur. J. Heart Fail. 14 (2012) 1322-1331.
86. P. Milberg, G. Frommeyer, S. Ghezelbash, et al., Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: Prolongation of interatrial conduction time and increase in post-repolarization refractoriness, Europace 15 (2013) 761-769.
87. R.L. Verrier, V.P. Pagotto, A.F. Kanas, et al., Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia, Heart Rhythm. 10 (2013) 121-127.